Auriga Reiterates Bullish Stance On Sequenom (SQNM) On Commercial Viability of T21 test
Tweet Send to a Friend
Auriga reiterates a 'Buy' rating and $9.00 price target on Sequenom (Nasdaq: SQNM) citing increased confidence in the commercial potential ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
